palforzia
aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.
bylvay
albireo - odevixibat - cholestasis, intrahepatic - galde og lever terapi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 og 5.
klisyri
almirall, s.a. - tirbanibulin - keratose, actinic - antibiotika og kemoterapeutiske midler til dermatologisk brug - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.
lalstop g46 wg vanddispergerbart granulat
danstar ferment ag - clonostachys - vanddispergerbart granulat - 1000000000 cfu/kg clonostachys rosea stamme j1446 (=gliocladium catenulatum stamme j1446)
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
lalstop contans wg vanddispergerbart granulat
danstar ferment ag - coniothyrium - vanddispergerbart granulat - 1000000000000 cfu/kg coniothyrium minitans
paxene
norton healthcare ltd. - paclitaxel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastiske midler - paxene er indiceret til behandling af patienter med:• avanceret aids-relateret kaposis sarkom (aids-aa), der har undladt før liposomal antracyklin terapi;• metastatisk karcinom i brystet (mbc), der har svigtet, eller ikke er kandidater til standard antracyklin-holdig terapi;• avanceret ovariecancer (aoc) eller med residual sygdom (> 1 cm) efter indledende laparotomi, i kombination med cisplatin som første-linje-behandling;• metastatisk ovariecancer (moc) efter svigt af platin-med kombinationsbehandling uden taxaner som anden linie behandling.• ikke-småcellet lungekræft (nsclc), der ikke er kandidater til potentielt helbredende operation og/eller strålebehandling i kombination med cisplatin. begrænsede effektivitetsdata understøtter denne indikation (se afsnit 5.
fludarabinphosphat "pharmachemie" 25 mg/ ml koncentrat til injektions-/infusionsvæske, opløsning
pharmachemie b.v. - fludarabinphosphat - koncentrat til injektions-/infusionsvæske, opløsning - 25 mg/ ml
febuxostat "accord" 120 mg filmovertrukne tabletter
accord healthcare b.v. - febuxostat - filmovertrukne tabletter - 120 mg
febuxostat "accord" 80 mg filmovertrukne tabletter
accord healthcare b.v. - febuxostat - filmovertrukne tabletter - 80 mg